Mucosal adjuvants

Current HIV Research

Volumn 8, Issue 4, 2010, Pages 330-335

  Harandi, Ali M ^a   Medaglini, Donata ^b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

Adjuvant; Mucosal adjuvant; Mucosal immunity; Mucosal vaccine; Toll like receptor; Vaccine

Indexed keywords

ADJUVANT; BACTERIAL TOXIN; CHOLERA VACCINE; ENTEROTOXIN; ESCHERICHIA COLI VACCINE; HEPATITIS B VACCINE; INFLUENZA VACCINE; LIVE VACCINE; LTK 63; NASALFLU; ORAL POLIOMYELITIS VACCINE; PHOSPHORYL LIPID A; ROTAVIRUS VACCINE; TOLL LIKE RECEPTOR 9 AGONIST; TOLL LIKE RECEPTOR AGONIST; TYPHOID VACCINE; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG DELIVERY SYSTEM; FACIAL NERVE PARALYSIS; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOSTIMULATION; MUCOSAL IMMUNITY; NONHUMAN; WEGENER GRANULOMATOSIS;

ADJUVANTS, IMMUNOLOGIC; HUMANS; IMMUNITY, INNATE; IMMUNITY, MUCOSAL; RECEPTORS, IMMUNOLOGIC; TOLL-LIKE RECEPTORS; VACCINATION; VACCINES;

EID: 77953495389     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016210791208695     Document Type: Article

References (83)

1. Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 2006; 6: 148-58.
2. Brandtzaeg P, Kiyono H, Pabst R, Russel MW. Terminology: nomenclature of mucosa-associated lymphoid tissue. Mucosal Immunol 2008; 1: 31-7.
3. Kiyono H, Fukuyama S. NALT- versus Peyer's-Patch-mediated mucosal immunity. Nat Rev 2004; 4: 699-710.
4. Moldoveanu A, Russel MW, Wu HY, Huang WQ, Compans RW, Mestecky J. Compartmentalization within the common mucosal immune system. Adv Exp Med Biol 1995; 371: 97-101.
5. Wu HY, Russel MW. Nasal lymphoid tissue, intranasal immunization, and compartmentalization of the common mucosal immune system. Immunol Res 1997; 16: 187-201.
6. + T cells in nasal mucosa-associated lymphoid tissue following intranasal immunization with recombinant Streptococcus gordonii. Infect Immun 2006; 74: 2760-6.
7. Pettini E, Ciabattini A, Pozzi G, Medaglini D. Adoptive transfer of transgenic T cells to study mucosal adjuvants. Methods 2009; 49: 340-5.
8. + cells in the genital and intestinal tracts. Vaccine 2010; 28: 1226-33.
9. Brandtzaeg P. Induction of secretory immunity and memory at mucosal surfaces. Vaccine 2007; 25: 5467-84.
10. Jespers V, Harandi AM, Hinkula J, et al. Assessment of mucosal immunity to HIV-1. Exp Rev Vacc 2010; in press.
11. Ogra PL, Faden H, Welliver RC. Vaccination Strategies for Mucosal Immune Responses. Clin Microbiol Rev 2001; 14: 430-45.
12. Russel MW, Mestecky J. Humoral immune responses to microbial infections in the genital tract. Microbes Infect 2002; 4: 667-77.
13. Lewis DJM, Huo Z, Barnett S, et al. Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS ONE 2009; 4: 1-5.
14. Mestecky J, Nguyen H, Czerkinsky C, Kiyono H. Oral immunization: an update. Gastroenterology 2008; 24: 713-9.
15. Mestecky J, Moldoveanu Z, Russell MW. Immunologic uniqueness of the genital tract: challenge for vaccine development. Am J Reproduct Immunol 2005; 53: 208-14.
16. Wira CR, Fahey JV, Sentman CL, Pioli PA, Shen L. Innate and adaptive immunity in female genital tract: cellular responses and interactions. Immunol Rev 2005; 206: 306-35.
17. Tengvall S, Lundqvist A, Eisenberg RJ, Cohen GH, Harandi AM. Mucosal administration of CpG oligodeoxynucleotide elicits strong CC and CXC chemokine responses in the vagina and serves as a potent Th1-tilting adjuvant for recombinant gD2 protein vaccination against genital herpes. J Virol 2006; 80: 5283-91.
18. Kwant A, Rosenthal KL. Vaccine 2004; 22: 3098-104.
19. Lindqvist M, Persson J, Thorn K, Harandi AM. The mucosal adjuvant effect of alpha-galactosylceramide for induction of protective immunity to sexually transmitted viral infection. J Immunol 2009; 182: 6435-43.
20. Singh SR, Hullet K, Pillai SR, Dennis VA, Oh MK, Scissum-Gunn K. Mucosal immunization with recombinant MOMP genetically linked with modified cholera toxin confers protection against Chlamydia trachomatis infection. Vaccine 2006; 24: 1213-24.
21. Tengvall S, O'Hagan D, Harandi AM. Rectal immunization generates protective immunity in the female genital tract against herpes simplex virus type 2 infection: relative importance of myeloid differentiation factor 88. Antiviral Res 2008; 78: 202-14.
22. Fraillery D, Zosso N, Nardelli-Haefliger D. Rectal and vaginal immunization of mice with human papillomavirus L1 virus-like particles. Vaccine 2009; 27: 2326-34.
23. Kwant A, Rosenthal KL. Intravaginal immunization with viral subunit protein plus CpG oligodeoxynucleotides induces protective immunity against HSV-2. Vaccine 2004; 22: 3098-104.
24. Wassen L, Jertborn M. Kinetics of local and systemic immune responses after vaginal immunization with recombinant cholera toxin B subunit in humans. Clin Diagn Lab Immunol 2005; 12: 447-52.
25. Lindqvist M, Navabi N, Jansson M, et al. Local cytokine and inflammatory responses to candidate vaginal adjuvants in mice. Vaccine 2009; 28: 270-8.
26. Song J, Nguyen HH, Cuburu N, et al. Sublingual vaccination with influenza virus protects mice against lethal viral infection. Proc Natl Acad Sci USA 2008; 105: 1644-9.
27. Song JH, Kim J-I, Kwon H-J, et al. CCR7-CCL19/CCL21- regulated dendritic cells are responsible for effectiveness of sublingual vaccination. J Immunol 2009; 182: 6851-60.
28. Reed SG, Bertholet S, Coler RN, Friede M. New horizons in adjuvants for vaccine development. Trends Immunol 2009; 30: 23-32.
29. Ahlers JD, Belyakov IM. Strategies for optimizing targeting and delivery of mucosal HIV vaccines. Eur J Immunol 2009; 39: 2657-69.
30. Singh M, O'Hagan. Recent advances in vaccine adjuvants. Pharm Res 2002; 19: 715-28.
31. Mutsch M, Zhou W, Rhodes P, et al. Use of the inactivated influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med 2004; 350: 896-903.
32. Asturias EJ, Halpern J, Torres OR, et al. Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial. Lancet 2008; 371: 2019-25.
33. Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med 2005; 11: 45-53.
34. Pizza M, Fontana MR, Giuliani MM, et al. A genetically detoxified derivative of heat-labile Escherichia coli enterotoxin induces 307 neutralizing antibodies against the A subunit. J Exp Med 1994; 180: 2147-53.
35. Stephenson I, Zambon MC, Rudin A, et al. Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers. J Virol 2006; 80: 4962-70.
36. Tritto E, Muzzi A, Pesce I, et al. The acquired immune response to the mucosal adjuvant LTK63 imprints the mouse lung with a protective signature. J Immunol 2007; 179: 5346-57.
37. Giuliani MM, Del Giudice G, Giannelli V, et al. Mucosal adjuvanticity and immunogenicity of LTR72, a novel nutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity. J Exp Med 1998; 187: 1123-32.
38. Dickinson BL, Clements JD. Dissociation of Escherichia coli heat- labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect Immun 1995; 63: 1617-23.
39. Summerton NA, Welch RW, Bondoc L, et al. Toward the development of a stable, freeze-dried formulation of Helicobacter pylori killed whole cell vaccine adjuvanted with a novel mutant of Escherichia coli heat-labile toxin. Vaccine 2010; 28(5): 1404-11.
40. McNeal MM, Basu M, Nean JA, et al. Intrarectal immunization of mice with VP6 and either LT(R192G) or CTA1-DD as adjuvant protects against fecal rotavirus shedding after EDIM challenge. Vaccine 2007; 25: 6224-31.
41. Sundling C, Schon K, Morner A, et al. CTA1-DD adjuvant promotes strong immunity against human immunodeficiency virus type 1 envelope glycoproteins following mucosal immunization. J Gen Virol 2008; 89: 2954-64.
42. Cunningham KA, Carey AJ, Lycke N, Timms P, Beagley KW. CTA1-DD is an effective adjuvant for targeting anti-chlamydial immunity to the murine genital mucosa. J Reprod Immunol 2009; 81: 34-8.
43. Agren LC, Ekman L, Löwenadler B, Nedrud JG, Lycke NY. Adjuvanticity of the cholera toxin A1-based gene fusion protein, CTA1-DD, is critically dependent on the ADP-ribosyltransferase and Ig-binding activity. J Immunol 1999; 162: 2432-40.
44. Sanchez J, Holmgren J. Cholera toxin structure, gene regulation and pathophysiological and immunological aspects. Cell Mol Life Sci 2008; 65: 1347-60.
45. Boyaka PN, Ohmura M, Fujihashi K, et al. Chimeras of labile toxin one and cholera toxin retain mucosal adjuvanticity and direct Th cell subsets via their B subunit. J Immunol 2003; 170: 454-62.
46. Wassen L, Schon K, Holmgren J, Jertborn M, Lycke N. Local intravaginal vaccination of the female genital tract. Scand J immunol 1996; 44: 408-14.
47. Bergquist C, Johansson EL, Lagergard T, Holmgren J, Rudin A. Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina. Infect Immun 1997; 65: 2676-84.
48. Jertborn M, Nordström I, Kilander A, Czerkinsky C, Holmgren J. Local and systemic immune responses to rectal administration of recombinant cholera toxin B subunit in humans. Infect Immun 2001; 69: 4125-8.
49. Holmgren J, Bergquist C. Oral B subunit killed whole-cell cholera vaccines. In: Levine MM, editor. New Generation Vaccines. New York, 2004: 499-510.
50. Lucas ME, Deen JL, Von Seidlein L, et al. Effectiveness of mass oral cholera vaccination in Beira, Mozambique. N Engl J Med 2005; 352: 757-67.
51. Adamsson J, Lindblad M, Lundqvist A, Kelly DJ, Holmgren J, Harandi AM. Novel Immunostimulatoy agent based on CpG oligodeoxynucleotide linked to the nontoxic B subunit of cholera toxin. J Immunol 2006; 176: 4902-13.
52. Nystrom-Asklin J, Adamsson J, Harandi AM. The adjuvant effect of CpG oligodeoxynucleotide linked to the non-toxic B subunit of cholera toxin for induction of immunity against H. pylori in mice. Scand J immunol 2008; 67: 431-40.
53. Klinman DM, Klaschik S, Sato T, Tross D. CpG oligonuclleotides as adjuvants for vaccines targeting infectious diseases. Advanced Drug Delivery Rev 2009; 61: 248-55.
54. Harandi AM, Holmgren J. CpG DNA as a potent inducer of mucosal immunity: implications for immunoprophylaxis and immunotherapy of mucosal infections. Curr Opin Investig Drugs 2004; 5: 141-5.
55. Ko SY, Ko HJ, Chang WS, Park SH, Kweon MN. alpha- Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor. J Immunol 2005; 175: 3309-17.
56. Moyle PM, McGeary RP, Toth B, Toth B. Mucosal Immunisation: Adjuvants and Delivery Systems. Curr Drug Deliv 2004; 1: 385-96.
57. Harandi AM, Medaglini D, Shattock RJ, Working Group convened by Europrice. Vaccine adjuvanys: A priority for vaccine research. Vaccine 2010; 28: 2363-66.
58. Medaglini D, Olesen OF, Rappuoli R. The European effort towards the development of mucosal vaccines for poverty-related diseases. Vaccine 2009; 27: 2641-8.
59. Shi W, Liu J, Huang Y, Quiao L. Papillomavirus pseudovirus: a novel vaccine to induce mucosal and systemic cytotoxic T- lymphocyte responses. J Virol 2001; 75: 10139-48.
60. Guerrero RA, Ball JM, Krater SS, Pacheco SE, Clements JD, Estes MK. Recombinant Norwalk virus-like particles administered intranasally to mice induce systemic and mucosal (fecal and vaginal) immune responses. J Virol 2001; 75: 9713-22.
61. Niikura M, Takamura S, Kim G, et al. Chimeric recombinant hepatitis E virus-like particles as an oral vaccine vehicle presenting foreign epitopes. Virology 2002; 293: 273-80.
62. Lavelle EC, O'Hagan DT. Delivery systems and adjuvants for oral vaccines. Expert Opin Drug Deliv 2006; 3: 747-62.
63. Christensen D, Foged C, Rosenkrands I, et al. CAF01 liposomes as a mucosal vaccine adjuvant: In vitro and in vivo investigations. Int J Pharm 2009; Epub ahead of print.
64. Perez O, Bracho G, Lastre M, et al. Proteliposome-derived Cochleate as an immunomodulator for nasal vaccine. Vaccine 2006; 24: 53-3.
65. Del Campo J, Lindquist L, Cuello M, et al. Intranasal immunization with a proteoliposome-derived cochleate containing recombinant gD protein confers protective immunity against genital herpes in mice. Vaccine 2010; 28: 1193-200.
66. Johansson E-L, Wassen L, Holmgren J, Jertborn M, Rudin A. Nasal and vaginal vaccinations have differential effects on antibody responses in vaginal and cervical secretions in humans. Infect Immun 2001; 69: 7481-6.
67. Peppoloni S, Ruggiero G, Contorni M, Morandi M, Pizza M. Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines. Expert Rev Vaccines 2003; 2: 285-93.
68. Lapa JA, Sincock SA, Ananthakrishnan M, et al. Randomized clinical trial assessing the safety and immunogenicity of oral microencapsulated enterotoxigenic Escherichia coli surface antigen 6 with or without heat-labile enterotoxin with mutation R192G. Clin Vaccine Immunol 2008; 15: 1222-8.
69. McNeela EA, Jabbal-Gill I, Illum L, et al. Intranasal immunization with genetically detoxified diphtheria toxin induces T cell responses in humans: enhancement of Th2 responses and toxin- neutralizing antibodies by formulation with chitosan. Vaccine 2004; 22: 909-14.
70. Huo Z, Sinha R, Mc Neela EA, et al. Induction of protective serum meningococcal bactericidal and diphtheria-neutralizing antibodies and mucosal immunoglobulin A in volunteers by nasal insufflations of the Neisseria meningitidis serogroup C polysaccharide-CRM197 conjugate vaccine mixed with chitosan. Infect Immun 2005; 73: 8256-65.
71. Treanor J, Nolan C, O'Brien DP, et al. Intranasal administration of a proteosome-influenza vaccine is well-tolerated and induces serum and nasal secretion influenza antibodies in healthy human subjects. Vaccine 2006; 24: 254-62.
72. Couch RB. Nasal vaccination, Escherichia coli enterotoxin, and Bell's palsy. N Engl J Med 2004; 350: 860-1.
73. DeFrancesco L. Dynavax trial halted. Nat Biotechnol 2008; 26: 484.
74. Verstraeten T, Descamps D, David MP, et al. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvant vaccines. Vaccine 2008; 26: 6630-8.
75. Kubota M, Miller C, Imaoka K, Kawabat S, Fujihashi K, MJR, Kiyono H. Oral immunization with simian immunodeficiency virus p55gag and cholera toxin elicits both mucosal IgA and systemic IgG immune responses in nonhuman primates. J Immunol 1997; 158: 5321-9.
76. Imaoka K, Miller CJ, Kubota M, et al. Nasal immunization of nonhuman primates with simian immunodeficiency virus p55gag and cholera toxin adjuvant induces Th1/Th2 help for virus-specific immune responses in reproductive tissues. J Immunol 1998; 161: 5952-8.
77. Cuburu N, Kweon MN, Hervouet C, et al. Sublingual immunization with nonreplicating antigens induces antibody- forming cells and cytotoxic T cells in the female genital tract mucosa and protects against genital papillomavirus infection. J Immunol 2009; 183: 7851-9.
78. Song JH, Nguyen HH, Cuburu N, et al. Sublingual vaccination with influenza virus protects mice against lethal viral infection. Proc Natl Acad Sci USA 2008; 105: 1644-9.
79. Roberts M, Bacon A, Rappuoli R, et al. A mutant pertussis toxin molecule that lacks ADP-ribosyltransferase activity, PT-9K/129G, is an effective mucosal adjuvant for intranasally delivered proteins. Infect Immun 1995; 63: 2100-8.
80. Ohmura-Hoshino M, Yamamoto M, Yuki Y, Takeda Y, Kiyono H. Non-toxic Stx derivatives from Escherichia coli possess adjuvant activity for mucosal immunity. Vaccine 2004; 22: 3751-61.
81. Toka FN, Pack CD, Rouse BT. Molecular adjuvants for mucosal immunity. Immunol Rev 2004; 199: 100-12.
82. Read RC, Naylor SC, Potter CW, et al. Effective nasal influenza vaccine delivery using chitosan. Vaccine 2005; 23: 4367-74.
83. Glueck R. Pre-clinical and clinical investigation of the safety of a novel adjuvant for intranasal immunization. Vaccine 2001; 20: 42-4.